Who Generates More Revenue? Halozyme Therapeutics, Inc. or Alkermes plc

Biotech Revenue Battle: Alkermes vs. Halozyme

__timestamp	Alkermes plc	Halozyme Therapeutics, Inc.
Wednesday, January 1, 2014	618789000	75334000
Thursday, January 1, 2015	628335000	135057000
Friday, January 1, 2016	745694000	146691000
Sunday, January 1, 2017	903374000	316613000
Monday, January 1, 2018	1094274000	151862000
Tuesday, January 1, 2019	1170947000	195992000
Wednesday, January 1, 2020	1038756000	267594000
Friday, January 1, 2021	1173751000	443310000
Saturday, January 1, 2022	1111795000	660116000
Sunday, January 1, 2023	1663405000	829253000
Monday, January 1, 2024	1557632000

Unleashing the power of data

Revenue Showdown: Halozyme Therapeutics vs. Alkermes

In the competitive landscape of biotechnology, revenue generation is a key indicator of success. Over the past decade, Alkermes plc has consistently outperformed Halozyme Therapeutics, Inc. in terms of revenue. From 2014 to 2023, Alkermes saw a remarkable 169% increase in revenue, peaking at $1.66 billion in 2023. In contrast, Halozyme's revenue grew by over 1,000%, reaching $829 million in the same year. Despite this impressive growth, Halozyme's revenue remains about half of Alkermes'.

Alkermes' steady growth can be attributed to its diversified portfolio and strategic partnerships, while Halozyme's rapid rise highlights its innovative approaches in drug delivery. As both companies continue to evolve, investors and industry watchers will be keen to see if Halozyme can close the gap or if Alkermes will maintain its lead.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025